Which medications are appropriate to prescribe for vestibular neuritis, Ménière’s disease, and posterior‑canal BPPV?

Medication Management for Vestibular Neuritis, Ménière's Disease, and Posterior-Canal BPPV

Posterior-Canal BPPV: Avoid Routine Medication

Do not prescribe vestibular suppressants (antihistamines, benzodiazepines) for posterior-canal BPPV. 1 The American Academy of Otolaryngology–Head and Neck Surgery explicitly recommends against routine use of these medications because BPPV is a mechanical disorder requiring physical repositioning maneuvers, not pharmacotherapy. 1

Rationale for Avoiding Medications in BPPV

• Canalith repositioning procedures (Epley, Semont maneuvers) achieve approximately 80% symptom resolution within 1–3 treatment sessions, making them the definitive treatment. 2
• Vestibular suppressants such as meclizine, dimenhydrinate, and benzodiazepines do not address the underlying pathophysiology of displaced otoconia and may delay central vestibular compensation. 1
• Multiple studies confirm that medications offer no curative or prophylactic benefit in BPPV. 3

Limited Role for Symptomatic Relief

• Short-term antiemetics (e.g., ondansetron, prochlorperazine) may be prescribed solely for severe nausea or vomiting during acute episodes, but should be discontinued once repositioning maneuvers are performed. 4
• Benzodiazepines (e.g., diazepam, lorazepam) may provide temporary symptom relief but should be limited to 2–3 days maximum to avoid interfering with vestibular adaptation. 4

---

Vestibular Neuritis: Corticosteroids Are First-Line

Prescribe oral corticosteroids (methylprednisolone or prednisone) within 72 hours of symptom onset for vestibular neuritis. 5, 6 This is the only medication with proven efficacy for improving peripheral vestibular function recovery.

Evidence-Based Corticosteroid Regimen

• Methylprednisolone 100 mg daily for 3 days, then tapered over 10–14 days significantly improves vestibular function recovery at 12 months (mean improvement 62.4% vs. 39.6% with placebo, p<0.001). 5
• Meta-analysis of 15 trials (852 patients) confirms corticosteroids produce statistically significant benefit with an odds ratio of 2.4 (95% CI 1.3–4.4, p=0.004) for restoration of vestibular function and a number needed to treat of 7. 6
• Start treatment as early as possible—benefit is greatest when initiated within the first 3 days of symptom onset. 5, 7

Medications to Avoid in Vestibular Neuritis

• Do not prescribe valacyclovir or other antiviral agents—randomized controlled trial data show no benefit (mean improvement 36.0% vs. 39.6% with placebo, p=0.43), and combination therapy with corticosteroids offers no advantage over corticosteroid monotherapy. 5
• Betahistine has no established role in vestibular neuritis. 8, 4

Symptomatic Management

• Vestibular suppressants (dimenhydrinate 50 mg every 6 hours, meclizine 25 mg every 8 hours) should be limited to the first 2–3 days to control severe vertigo, nausea, and vomiting. 4, 7
• Prolonged use beyond 72 hours delays central compensation and should be avoided. 4, 7
• Antiemetics (ondansetron 4–8 mg every 8 hours, metoclopramide 10 mg every 6 hours) may be added for refractory nausea. 4

---

Ménière's Disease: Betahistine and Diuretics for Prophylaxis

Prescribe betahistine 16–48 mg three times daily as first-line prophylactic therapy to reduce the frequency of vertigo attacks in Ménière's disease. 8, 4 Although evidence quality is limited, betahistine is the most widely recommended medication by otolaryngology guidelines. 9

Betahistine Dosing and Mechanism

• Standard dosing: 16 mg three times daily, titrated up to 48 mg three times daily based on response. 4
• Betahistine is a histamine H1 agonist and H3 antagonist thought to improve microcirculation in the inner ear and reduce endolymphatic hydrops. 8
• Controlled trials suggest betahistine may reduce attack frequency, though the evidence base requires strengthening. 8

Diuretics as Adjunctive Therapy

• Hydrochlorothiazide 25 mg daily or acetazolamide 250 mg twice daily may be added to betahistine for patients with frequent attacks, based on the hypothesis that diuretics reduce endolymphatic fluid volume. 9
• Evidence for diuretics is weaker than for betahistine, but they are commonly used in clinical practice. 9

Acute Attack Management

• During acute vertigo attacks lasting 20 minutes to 12 hours, prescribe vestibular suppressants and antiemetics for symptomatic relief:
  • Dimenhydrinate 50 mg or meclizine 25 mg every 6–8 hours. 4
  • Prochlorperazine 5–10 mg or ondansetron 4–8 mg for nausea. 4
• Benzodiazepines (diazepam 2–5 mg, lorazepam 0.5–1 mg) may be used sparingly during severe attacks but should not be prescribed for chronic use. 4

Intratympanic Gentamicin for Refractory Cases

• Intratympanic gentamicin (0.3–0.6 mL of 40 mg/mL solution) is reserved for patients with disabling vertigo unresponsive to medical therapy, as it ablates vestibular function in the affected ear. 9, 4
• This is a destructive procedure with risk of hearing loss and should be performed only by otolaryngologists. 9

---

Key Pitfalls and Caveats

BPPV Mismanagement

• The most common error is prescribing meclizine or betahistine for BPPV instead of performing canalith repositioning maneuvers. 1, 2 This delays definitive treatment and exposes patients to unnecessary medication side effects.
• Patients with BPPV have a 12-fold increased fall risk; prolonged use of vestibular suppressants worsens balance and increases fall risk further. 2

Distinguishing Vestibular Neuritis from Stroke

• Vestibular neuritis presents with continuous vertigo lasting days, profound nausea, and absence of hearing loss, tinnitus, or aural fullness. 7
• Red-flag features requiring urgent neuroimaging include dysarthria, dysmetria, dysphagia, focal motor/sensory deficits, Horner's syndrome, or direction-changing nystagmus without head-position changes. 2
• If red flags are present, do not prescribe corticosteroids empirically—obtain MRI to exclude posterior-circulation stroke. 2

Ménière's Disease Diagnostic Criteria

• Ménière's disease requires documented fluctuating low- to mid-frequency sensorineural hearing loss on audiometry, not just patient-reported hearing changes. 9
• Vertigo episodes must last 20 minutes to 12 hours; briefer episodes suggest BPPV, and longer episodes suggest vestibular migraine or other causes. 9
• Do not diagnose Ménière's disease based on vertigo alone—the triad of fluctuating hearing loss, tinnitus, and aural fullness must be present. 9

Corticosteroid Adverse Effects in Vestibular Neuritis

• The number needed to harm with corticosteroids is 4 (95% CI 3–19), primarily due to hyperglycemia, insomnia, and gastrointestinal upset. 6
• Screen for contraindications (uncontrolled diabetes, active peptic ulcer, severe osteoporosis) before prescribing. 6

---

Summary Algorithm

For Posterior-Canal BPPV:

1. Perform Dix-Hallpike test and canalith repositioning maneuver (Epley or Semont). 1, 2
2. Do not prescribe vestibular suppressants or betahistine. 1
3. Reserve short-term antiemetics (≤3 days) for severe nausea only. 4

For Vestibular Neuritis:

1. Prescribe methylprednisolone 100 mg daily × 3 days, then taper over 10–14 days, starting within 72 hours of onset. 5, 6
2. Do not add valacyclovir. 5
3. Limit vestibular suppressants to 2–3 days for acute symptom control. 4, 7

For Ménière's Disease:

1. Prescribe betahistine 16 mg three times daily, titrate to 48 mg three times daily. 8, 4
2. Add hydrochlorothiazide 25 mg daily or acetazolamide 250 mg twice daily if attacks persist. 9
3. Use vestibular suppressants and antiemetics only during acute attacks. 4
4. Refer for intratympanic gentamicin if medical therapy fails. 9, 4